AstraZeneca (AZN) Given a GBX 6,350 Price Target at Credit Suisse Group
A number of other research firms have also issued reports on AZN. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Wednesday, August 15th. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research note on Monday, September 24th. HSBC set a GBX 4,840 ($63.24) price objective on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, August 15th. Barclays reiterated an overweight rating on shares of AstraZeneca in a research note on Monday, September 24th. Finally, UBS Group reiterated a neutral rating and set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca in a research note on Tuesday, September 25th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and an average price target of GBX 5,927.44 ($77.45).
LON AZN traded down GBX 28 ($0.37) during mid-day trading on Friday, hitting GBX 5,927 ($77.45). The company’s stock had a trading volume of 2,638,281 shares, compared to its average volume of 2,310,000. AstraZeneca has a 52-week low of GBX 4,260 ($55.66) and a 52-week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What is a Derivative?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.